Sonosemi Medical

Sonosemi Medical, founded in April 2020 in Shenzhen, China, is an emerging player in the healthcare industry, dedicated to enhancing medical treatment through intelligent technology. Specializing in high-end pan-vascular interventional medical devices, the company is renowned for its pioneering work in coronary artery disease, peripheral vascular disease, and structural heart disease.

Notably, Sonosemi Medical has achieved significant milestones, including China's first domestic coronary intravascular lithotripsy system approval and advancement in developing a domestic intracardiac echocardiography (ICE) system. With intellectual property independently owned, the company is positioned as a leader in innovative product development.

Boasting a team of about two hundred industry experts, and strategic collaboration with global partners, Sonosemi is aggressively driving the commercialization of its products. The company recently secured a CNY200.00M Series B investment on 26 October 2023 with contributions from investors like Eight Roads Ventures and Tencent, highlighting strong investor confidence in its growth trajectory and market potential.